ENTITY
Sinomab Bioscience Ltd

Sinomab Bioscience Ltd (3681 HK)

12
Analysis
Health Care • Hong Kong
Sinomab Bioscience Limited manufactures antibody drugs. The Company researches, develops, and manufactures anti-infective drugs, antitumor agents, and monoclonal antibodies. Sinomab Bioscience markets its products worldwide.
more
bullish•InnoCare Pharma Ltd
•04 Mar 2020 13:24

InnoCare (čÆŗčÆšå„åŽ) Pre-IPO: PHIP and Valuation Update

InnoCare Pharma Limited is a clinical-stage biopharmaceutical company with a focus on small molecule inhibitors for BTK, and FGFRs. The company...

Logo
627 Views
Share
bullish•InnoCare Pharma Ltd
•28 Jan 2020 12:49

InnoCare (čÆŗčÆšå„åŽ) Pre-IPO: Thoughts on Valuation

InnoCare Pharma Limited is a clinical-stage biopharmaceutical company with a focus on small molecule inhibitors for BTK, and FGFRs. The company...

Logo
618 Views
Share
bullish•Alibaba
•15 Jan 2020 10:06

Aequitas 2019 IPOs and Placements Performance - Things We Got Right/Wrong and Things We Plan to Do

2019 marked our first full year of operations as an Independent Research Company, post spin-off from Smartkarma in August 2018. With our...

Logo
722 Views
Share
•12 Nov 2019 11:05

SinoMab (äø­å›½ęŠ—ä½“) Post-IPO Trading: Decent Retail Interests Can't Save the Day

SinoMab's IPO was priced at the low end and started trading today. We have highlighted in our earlier note that 1) the company's core product...

Logo
436 Views
Share
bullish•Tyro Payments
•09 Nov 2019 12:56

ECM Weekly (9 Nov 2019) - Phoenix Tree, I-Mab, Tyro Payments, Pharmaron, Heaven-Sent

Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs. Hong Kong...

Share
x